Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.700
0.00 (0.00%)
At close: Apr 14, 2026, 4:00 PM EDT
1.690
-0.010 (-0.59%)
After-hours: Apr 14, 2026, 4:00 PM EDT

Chemomab Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-9-13.95-24.22-27.65-12.48
Depreciation & Amortization
0.070.050.070.060.03
Stock-Based Compensation
0.620.621.493.212.02
Other Operating Activities
0.01----
Change in Accounts Receivable
-1.14-0.490.9-0.06-2.06
Change in Accounts Payable
-0.180.12-1.170.351.18
Change in Other Net Operating Assets
-1.52-1.74-0.683.72-1.07
Operating Cash Flow
-11.13-15.39-23.61-20.37-12.37
Capital Expenditures
-0--0-0.07-0.24
Sale of Property, Plant & Equipment
----1
Investment in Securities
5.392.315.8819.6-45.95
Other Investing Activities
----0
Investing Cash Flow
5.392.315.8819.53-45.19
Issuance of Common Stock
7.169.873.50.4158.65
Repurchase of Common Stock
----1.22-
Other Financing Activities
----2.43
Financing Cash Flow
7.169.873.5-0.8161.07
Net Cash Flow
1.42-3.22-4.23-1.653.51
Free Cash Flow
-11.13-15.39-23.61-20.44-12.61
Free Cash Flow Per Share
-1.75-3.43-8.04-7.18-4.86
Cash Income Tax Paid
---0.19-0.35-
Levered Free Cash Flow
-8.2-10.86-15.49-10.87-6.07
Unlevered Free Cash Flow
-8.2-10.86-15.49-10.87-6
Change in Working Capital
-2.84-2.11-0.954.01-1.95
Updated Mar 19, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q